# Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma

> **NCT04048343** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 65 (actual)

## Conditions studied

- Severe Asthma

## Interventions

- **DRUG:** Biological: Experimental: Tezepelumab

## Key facts

- **NCT ID:** NCT04048343
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-10
- **Primary completion:** 2021-03-18
- **Final completion:** 2021-03-18
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2022-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04048343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04048343, "Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04048343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*